Xiaoping Li

Dr. Xiaoping Li


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in Interdisciplinary Sciences: Computational Life Sciences
Verified
Journal Article
Closed access
PDF file
LZLiping Zeng
Liping Zeng
YLYunchang Liu
Yunchang Liu
XLXiaoping Li
Xiaoping Li
XGXue Gong
Xue Gong
MTMiao Tian
Miao Tian
CZChunyu Zeng
Chunyu Zeng

1 April 2026 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
ZLZhong Li
Zhong Li
CLConghui Li
Conghui Li
HZHan Zhan
Han Zhan
DCDingqin Cai
Dingqin Cai
YOYangyu Ou
Yangyu Ou
LLLimin Liu
Limin Liu
Background: Doxorubicin (DOX) can induce significant cardiotoxicity and compromise the safety of its clinical application. This study explored the cardioprotective potential of tirzepatide against DOX-induced cardiotoxicity. Methods: In this study, we employed both in vitro and in vivo DOX injury models to systematically assess cardiac function and myocardial tissue structure through echocardiography and histopathological analysis. Additionally, we examined mitochondrial ultrastructure using transmission electron microscopy (TEM) and evaluated mitochondrial membrane potential (MMP). Results: Our findings revealed that tirzepatide administration significantly enhanced cardiac systolic performance and reduced myocardial damage. Notably, tirzepatide effectively preserved mitochondrial function by maintaining cristae integrity and restoring MMP. Conclusions: These results demonstrate that tirzepatide confers protection against DOX-induced cardiotoxicity primarily through the amelioration of mitochondrial dysfunction.